



Australian Clinical Labs Limited

ABN 94 645 711 128

Registered Office:

1868-1892 Dandenong Road

Clayton VIC 3168

Australia

clinicallabs.com.au

Friday, 22 September 2023

Takeover Offer for Healius Limited – update on the ACCC’s review timeline

Australian Clinical Labs Limited (**ACL**) refers to its off-market takeover offer for all of the fully paid ordinary shares on issue in Healius Limited (**Healius**), the terms and conditions of which are set out in ACL’s replacement bidder’s statement dated 14 April 2023 (**Bidder’s Statement**) (as supplemented by ACL’s second supplementary bidder’s statement dated 22 May 2023 (**Second Supplementary Bidder’s Statement**)) and as varied by ACL’s notice of variation dated 20 July 2023) (the **Offer**). Capitalised terms used in this announcement have the same meanings given to them in the Bidder’s Statement, unless the context requires otherwise.

ACL refers to its announcement to the ASX on 20 July 2023, in which it advised that the Australian Competition and Consumer Commission (**ACCC**) had released a Statement of Issues in respect of the Proposed Merger and indicated that it expected to announce its final decision in respect of the Proposed Merger on 12 October 2023.

ACL notes that the ACCC has advised ACL that it has suspended the timeline on its public register of its review of the Proposed Merger pending the receipt by the ACCC of further information (and has updated its public register to that effect).

The effect of the suspension of the timeline is that the date on which the ACCC expects to announce its final decision in respect of the Proposed Merger will be delayed. The ACCC has not yet publicly stated or advised ACL of its new expected decision date.

The Offer is currently open for acceptance until 7:00pm (Sydney time) on Friday, 17 November 2023 (unless extended or withdrawn in accordance with the Corporations Act), and the ACL EGM (at which ACL Shareholders will vote on the proposed issue of ACL Shares to Healius Shareholders as Offer Consideration for the purposes of the applicable ASX Listing Rules) is currently scheduled to be held at 10:00am (Sydney time) on Tuesday, 7 November 2023.

ACL will consider and determine whether to extend the Offer Period and/or postpone the ACL EGM at the appropriate time. ACL will update ACL Shareholders and Healius Shareholders in relation to these matters at the appropriate time.

– ENDS –

This announcement was authorised for release to the ASX by the ACL Board.

ASX Announcement

For further information regarding this announcement, please contact:

Investors

Eleanor Padman
Company Secretary
Email: epadman@padmanadvisory.com.au
Phone: +61 (0) 422 002 918

Media

Clive Mathieson, Sue Cato
Email: clive@catoandclive.com
cato@catoandclive.com
Phone: +61 (0) 411 888 425
+61 (0) 419 282 319

About Australian Clinical Labs

ACL is a leading Australian private provider of pathology services. Our NATA accredited laboratories perform a diverse range of pathology tests each year for a range of clients including doctors, specialists, patients, hospitals and corporate clients. ACL is one of the largest private hospital pathology businesses nationally. ACL is focused on its mission of combining talented people, and medical and scientific leadership, with innovative thinking and technologies to empower decision making that saves and improves patients' lives.